233 related articles for article (PubMed ID: 11530188)
21. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
Bray M; Martinez M; Smee DF; Kefauver D; Thompson E; Huggins JW
J Infect Dis; 2000 Jan; 181(1):10-9. PubMed ID: 10608745
[TBL] [Abstract][Full Text] [Related]
22. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment.
Smee DF; Gowen BB; Wandersee MK; Wong MH; Skirpstunas RT; Baldwin TJ; Hoopes JD; Sidwell RW
Int J Antimicrob Agents; 2008 Apr; 31(4):352-9. PubMed ID: 18206353
[TBL] [Abstract][Full Text] [Related]
23. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.
Smee DF; Wandersee MK; Bailey KW; Wong MH; Chu CK; Gadthula S; Sidwell RW
Antiviral Res; 2007 Jan; 73(1):69-77. PubMed ID: 16712967
[TBL] [Abstract][Full Text] [Related]
24. Parapoxviruses are strongly inhibited in vitro by cidofovir.
Nettleton PF; Gilray JA; Reid HW; Mercer AA
Antiviral Res; 2000 Dec; 48(3):205-8. PubMed ID: 11164507
[TBL] [Abstract][Full Text] [Related]
25. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Kaneko H; Mori S; Suzuki O; Iida T; Shigeta S; Abe M; Ohno S; Aoki K; Suzutani T
Antiviral Res; 2004 Jan; 61(1):63-6. PubMed ID: 14670595
[TBL] [Abstract][Full Text] [Related]
26. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir.
Bray M; Martinez M; Kefauver D; West M; Roy C
Antiviral Res; 2002 Jun; 54(3):129-42. PubMed ID: 12062386
[TBL] [Abstract][Full Text] [Related]
27. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Quenelle DC; Collins DJ; Kern ER
Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.
Keith KA; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 May; 48(5):1869-71. PubMed ID: 15105146
[TBL] [Abstract][Full Text] [Related]
30. Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.
Bolger G; Lapeyre N; Rhéaume M; Kibler P; Bousquet C; Garneau M; Cordingley M
Antiviral Res; 1999 Dec; 44(3):155-65. PubMed ID: 10651067
[TBL] [Abstract][Full Text] [Related]
31. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
Smee DF; Bailey KW; Wong MH; Tarbet EB
Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
[TBL] [Abstract][Full Text] [Related]
32. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.
Liu G; Zhai Q; Schaffner DJ; Wu A; Yohannes A; Robinson TM; Maland M; Wells J; Voss TG; Bailey C; Alibek K
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):201-6. PubMed ID: 15039095
[TBL] [Abstract][Full Text] [Related]
33. Cidofovir in the treatment of poxvirus infections.
De Clercq E
Antiviral Res; 2002 Jul; 55(1):1-13. PubMed ID: 12076747
[TBL] [Abstract][Full Text] [Related]
34. The activity of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses.
Gibson JS; Slater JD; Field HJ
Antiviral Res; 1992 Sep; 19(3):219-32. PubMed ID: 1332605
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
[TBL] [Abstract][Full Text] [Related]
36. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
Lalezari J; Schacker T; Feinberg J; Gathe J; Lee S; Cheung T; Kramer F; Kessler H; Corey L; Drew WL; Boggs J; McGuire B; Jaffe HS; Safrin S
J Infect Dis; 1997 Oct; 176(4):892-8. PubMed ID: 9333146
[TBL] [Abstract][Full Text] [Related]
38. Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless mice.
Smee DF; Dagley A; Downs B; Hagloch J; Tarbet EB
Antimicrob Agents Chemother; 2015 Jan; 59(1):520-6. PubMed ID: 25385098
[TBL] [Abstract][Full Text] [Related]
39. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Stals FS; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
[TBL] [Abstract][Full Text] [Related]
40. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
